Physician profile
Eric H Shen
NPI 1528140076
$8,221.66
in general payments reported to CMS, 2019-2025
35 companies · $2,339 in 2025
The $2,339 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $226 · 2021: $372 · 2022: $942 · 2023: $1,815 · 2024: $1,854 · 2025: $2,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,824 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,823.80 |
| Education | $184.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,969.88 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $817.97 | 2020-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $522.01 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $448.22 | 2020-2025 | Entyvio, Eohilia |
| Boston Scientific Corporation | $443.30 | 2019-2025 | General - Hemostasis, Resolution Clip |
| Genzyme Corporation | $412.66 | 2022-2025 | |
| Ardelyx, INC. | $316.46 | 2024-2025 | Ibsrela |
| Pfizer INC. | $309.89 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $253.41 | 2019-2024 | Linzess |
| Madrigal Pharmaceuticals | $231.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $219.09 | 2019-2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $154.94 | 2024-2025 | Voquezna |
| Celgene Corporation | $144.62 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $107.82 | 2024-2025 | Vowst |
| Braintree Laboratories, INC. | $99.95 | 2019-2025 | Sutab, Suflave |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $94.42 | 2025 | Omvoh |
| Exact Sciences Corporation | $84.13 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $73.28 | 2025 | Uplizna |
| Ipsen Biopharmaceuticals, INC | $65.19 | 2024-2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $62.93 | 2023-2025 | Ocaliva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.05 | 2023-2024 | Cyltezo |
| Novo Nordisk INC | $42.58 | 2023-2024 | Wegovy |
| Laborie Medical Technologies Corp. | $40.41 | 2024 | |
| Merck Sharp & Dohme LLC | $32.77 | 2019-2024 | Dificid |
| Coloplast Corp | $32.58 | 2019 | |
| Nestle Healthcare Nutrition INC. | $30.86 | 2022-2023 | |
| Shionogi INC | $29.24 | 2019 | |
| Echosens North America, INC. | $26.59 | 2019 | |
| Allergan, INC. | $24.22 | 2019 | |
| Ethicon US, LLC | $15.35 | 2019 | |
| Fresenius Kabi USA, LLC | $15.00 | 2023 | Idacio |
| Daiichi Sankyo INC. | $14.94 | 2019 | |
| Redhill Biopharma INC. | $14.00 | 2021 | |
| Alnylam Pharmaceuticals INC. | $13.57 | 2024 | Givlaari |
| Sandoz INC. | $13.39 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Shen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.